SCHEMBL7985907

SCHEMBL7985907

CCOC(=O)Cn1cc2c(n1)CC1CCC2N1C(=O)OCC

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.38
GAA P10253 1/20 0.38
KMT2A Q03164 2/20 0.38
ATM Q13315 2/20 0.37
ALDH1A1 P00352 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
LMNA P02545 1/20 0.35
MAPK1 P28482 1/20 0.35
GSK3A P49840 1/20 0.33
GSK3B P49841 1/20 0.33
MEN1 O00255 1/20 0.33
GPR65 Q8IYL9 1/20 0.32
CYP2C19 P33261 1/20 0.32
PKM P14618 1/20 0.32
HSD17B10 Q99714 1/20 0.32
JAK2 O60674 1/20 0.32
JAK1 P23458 1/20 0.32
TYK2 P29597 1/20 0.32
CHRM1 P11229 2/20 0.32
KDM4E B2RXH2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7993429 0.92 CHRM2 (0.36) L3MBTL1GAAKMT2AATMALDH1A1
SCHEMBL7989252 0.81 RAB9A (0.35) GAAKMT2AALDH1A1LMNAMAPK1
SCHEMBL7985658 0.78 CHRM2 (0.39) GAAJAK1CHRM1
SCHEMBL7986449 0.74 SMN1; SMN2 (0.40) KMT2AALDH1A1SMN1; SMN2LMNAMAPK1
SCHEMBL8221697 0.74 GPR65 (0.48) GPR65JAK2JAK1TYK2CHRM1
SCHEMBL11360559 0.74 CHRM1 (0.36) KMT2AALDH1A1MEN1GPR65CHRM1
Hydrochloric Acid SCHEMBL7987411 0.74 HTR2A (0.38) L3MBTL1GAAKMT2AATMALDH1A1
SCHEMBL28268013 0.73 KMT2A (0.36) L3MBTL1GAAKMT2AATMALDH1A1
SCHEMBL11368483 0.72 GPR65 (0.34) L3MBTL1GAAKMT2AALDH1A1SMN1; SMN2
SCHEMBL4051790 0.71 HPGD (0.40) L3MBTL1GAAKMT2AALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2001009125-A1 NOVEL 8-CARBONYL CHROMAN DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF AVENTIS PHARMA S.A. (FR) 2001-02-08 WO disclosed